These molecules were able to effectively retard tumor growth in vivo in combination with cetuximab in a heterotopic nude mouse model and in combination with an anti-neu antibody in a syngeneic mammary tumor model in Balb/c mice. This evidence concerns the gene ERBB2 and breast cancer.